F2G’s attempt to end a two-decade drought in novel therapies for invasive fungal infections has hit a hurdle after the FDA said it was unable to approve its olorofim candidate. The US regulator ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback